Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
HUTCHMED (China) Limited ( (HK:0013) ) has provided an update.
HUTCHMED (China) Limited has received full approval from the China National Medical Products Administration for its drug ORPATHYS® (savolitinib) to treat patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations. This approval expands the indication to include treatment-naïve patients and converts the prior conditional approval for previously treated patients to full approval. The decision is based on positive efficacy and safety data from a Phase IIIb clinical trial. This approval reinforces ORPATHYS® as a transformative treatment option for NSCLC and signifies a major advancement in addressing unmet medical needs in lung cancer, potentially improving outcomes for a significant patient population.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited operates within the pharmaceutical industry, focusing on the development and commercialization of targeted therapies. Its primary products include treatments for cancer, with a significant market focus in China. The company collaborates with AstraZeneca for the global development and commercialization of its therapies.
YTD Price Performance: 5.96%
Average Trading Volume: 72,066
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £2.18B
See more data about 0013 stock on TipRanks’ Stock Analysis page.
